New Jersey Senate Bill S797

New Jersey 2026-2027 Regular Session

• Introduced: 1/13/26
• Refer: 1/13/26

Caption

Requires Medicaid coverage for ovulation enhancing drugs and medical services related to administering such drugs for certain beneficiaries experiencing infertility.

Impact

If enacted, the bill would formally amend existing state laws governing Medicaid services by adding coverage for medically necessary treatments related to infertility. This change may result in increased accessibility to necessary medication and treatments for women facing difficulties in conceiving, which could also lead to a broader discussion on women's health rights and reproductive autonomy. Furthermore, the bill includes specific guidelines on the definition of infertility, setting clear parameters for eligibility.

Summary

Senate Bill 797 proposes to expand Medicaid coverage in New Jersey to include ovulation enhancing drugs and related medical services for eligible individuals experiencing infertility. This coverage specifically applies to beneficiaries aged 21 to 44 years, contingent on the availability of federal financial participation. This initiative closely mirrors similar benefits already in place in New York, highlighting a potential trend among states to enhance reproductive healthcare services under Medicaid.

Contention

While the bill may receive broad support from women's health advocates and those affected by infertility, it could also generate debate regarding healthcare funding and the implications for the state's Medicaid budget. Opponents may raise concerns about the financial strain of implementing new benefits amid existing constraints on public finances. Additionally, the specifics of limiting coverage to three cycles of treatment could also be a point of contention, as it may not meet the needs of all individuals seeking assistance with infertility.